URGENT.LY INC (ULY)

US9169311084 - Common Stock

0.8821  +0.05 (+5.89%)

After market: 0.9329 +0.05 (+5.76%)

Fundamental Rating

2

Taking everything into account, ULY scores 2 out of 10 in our fundamental rating. ULY was compared to 284 industry peers in the Software industry. Both the profitability and financial health of ULY have multiple concerns. ULY is not valued too expensively and it also shows a decent growth rate.



2

1. Profitability

1.1 Basic Checks

ULY had positive earnings in the past year.
In the past year ULY has reported a negative cash flow from operations.
In the past 5 years ULY reported 4 times negative net income.
ULY had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ULY has a Return On Assets of 104.76%. This is amongst the best in the industry. ULY outperforms 100.00% of its industry peers.
Industry RankSector Rank
ROA 104.76%
ROE N/A
ROIC N/A
ROA(3y)-12.82%
ROA(5y)-37.69%
ROE(3y)222.47%
ROE(5y)92.81%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Profit Margin, with a value of 44.78%, ULY belongs to the top of the industry, outperforming 97.54% of the companies in the same industry.
ULY has a Gross Margin of 21.75%. This is amonst the worse of the industry: ULY underperforms 83.80% of its industry peers.
In the last couple of years the Gross Margin of ULY has grown nicely.
Industry RankSector Rank
OM N/A
PM (TTM) 44.78%
GM 21.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.07%
GM growth 5YN/A

0

2. Health

2.1 Basic Checks

ULY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ULY has more shares outstanding
Compared to 1 year ago, ULY has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.72, we must say that ULY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ULY (-3.72) is worse than 83.80% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.72
ROIC/WACCN/A
WACC21%

2.3 Liquidity

ULY has a Current Ratio of 0.69. This is a bad value and indicates that ULY is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.69, ULY is doing worse than 87.32% of the companies in the same industry.
ULY has a Quick Ratio of 0.69. This is a bad value and indicates that ULY is not financially healthy enough and could expect problems in meeting its short term obligations.
ULY's Quick ratio of 0.69 is on the low side compared to the rest of the industry. ULY is outperformed by 86.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.69
Quick Ratio 0.69

5

3. Growth

3.1 Past

ULY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 182.43%, which is quite impressive.
ULY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.15%.
ULY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 679.41% yearly.
EPS 1Y (TTM)182.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.17%
Revenue 1Y (TTM)-16.15%
Revenue growth 3Y679.41%
Revenue growth 5YN/A
Sales Q2Q%-21.47%

3.2 Future

The Earnings Per Share is expected to grow by 26.08% on average over the next years. This is a very strong growth
ULY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.81% yearly.
EPS Next Y38.25%
EPS Next 2Y35.72%
EPS Next 3Y26.08%
EPS Next 5YN/A
Revenue Next Year-18.29%
Revenue Next 2Y-0.82%
Revenue Next 3Y5.81%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 0.16, the valuation of ULY can be described as very cheap.
Based on the Price/Earnings ratio, ULY is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 30.59, ULY is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for ULY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 0.16
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ULY's earnings are expected to grow with 26.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y35.72%
EPS Next 3Y26.08%

0

5. Dividend

5.1 Amount

ULY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

URGENT.LY INC

NASDAQ:ULY (9/20/2024, 8:26:30 PM)

After market: 0.9329 +0.05 (+5.76%)

0.8821

+0.05 (+5.89%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap11.85M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 0.16
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 104.76%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) 44.78%
GM 21.75%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.34
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.69
Quick Ratio 0.69
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)182.43%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y38.25%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-16.15%
Revenue growth 3Y679.41%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y